Comparison between Archidply Industries IPO and Bafna Pharmaceuticals IPO.
Archidply Industries IPO is a Mainboard Fixed Price IPO proposed to list at BSE, NSE while Bafna Pharmaceuticals IPO is a Mainboard Fixed Price proposed to list at BSE.
The total issue size of Archidply Industries IPO is up to ₹48.96 Cr whereas the issue size of the Bafna Pharmaceuticals IPO is up to ₹25.60 Cr. The final issue price of Archidply Industries IPO is ₹74.00 per share and of Bafna Pharmaceuticals IPO is ₹40.00 per share.
| Archidply Industries IPO | Bafna Pharmaceuticals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹70.00 per share | |
| Issue Price (Upper) | ₹80.00 per share | |
| Issue Price (Final) | ₹74.00 per share | ₹40.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 75 shares | |
| Fresh Issue Size | 66,15,720 shares | 64,00,206 shares |
| Fresh Issue Size (Amount) | up to ₹48.96 Cr | up to ₹25.60 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 66,15,720 shares | 64,00,206 shares |
| Issue Size Total (Amount) | up to ₹48.96 Cr | up to ₹25.60 Cr |
Archidply Industries IPO opens on Jun 11, 2008, while Bafna Pharmaceuticals IPO opens on May 27, 2008. The closing date of Archidply Industries IPO and Bafna Pharmaceuticals IPO is Jun 17, 2008, and May 30, 2008, respectively.
| Archidply Industries IPO | Bafna Pharmaceuticals IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Jun 11, 2008 | May 27, 2008 |
| Issue Close | Jun 17, 2008 | May 30, 2008 |
| Basis Of Allotment (Tentative) | ||
| Initiation of Refunds (Tentative) | ||
| Credit of Share (Tentative) | ||
| Listing date (Tentative) | Jul 04, 2008 | Jun 27, 2008 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Archidply Industries IPO P/E ratio is , as compared to Bafna Pharmaceuticals IPO P/E ratio of .
| Archidply Industries IPO | Bafna Pharmaceuticals IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | 97.68 | 71.07 | ||||
| Promoter Shareholding (Post-Issue) | 68.31 | 42.6 | ||||
| P/E Ratio | ||||||
| Market Cap | ₹162.80 Cr. | ₹63.92 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW | 21.87 | 10.65 |
In the Archidply Industries IPO Retail Individual Investors (RII) are offered 23,15,502 shares while in Bafna Pharmaceuticals IPO retail investors are offered 23,15,502 shares. Qualified Institutional Buyers (QIB) are offered 33,07,860 shares in Archidply Industries IPO and in Bafna Pharmaceuticals IPO.
| Archidply Industries IPO | Bafna Pharmaceuticals IPO | |
|---|---|---|
| Anchor Investor Reservation | ||
| Market Maker Reservation | ||
| QIB | 33,07,860 shares | |
| NII | 9,92,358 shares | 32,00,000 shares |
| RII | 23,15,502 shares | 32,00,000 shares |
| Employee | ||
| Others | ||
| Total | 66,15,720 shares | 64,00,000 shares |
Archidply Industries IPO subscribed 1.52x in total, whereas Bafna Pharmaceuticals IPO subscribed 4.88x.
| Archidply Industries IPO | Bafna Pharmaceuticals IPO | |
|---|---|---|
| QIB (times) | 0.20x | |
| NII (times) | 2.36x | 1.57x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 3.04x | 8.20x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 1.52x | 4.88x |
